Illustrative image.

Genvoya

Name: Genvoya
Brand: Gilead
Availability: InStock

Elvitegravir-Cobicistat-Emtricitabine-Tenofovir alafenamide

Prescription required

$6000.00

150/150/200/10mg · 3 × 30 tablets · 3 months supply

BrandBranded medicine· By Gilead

$2000.00 per month

How long a supply?

1 month$2000.00 a monthOne-off$2000.00

3 months$2000.00 a monthOne-off$6000.00

6 months$2000.00 a monthOne-off$12000.00

Supplied from Israel

Test mode: no payment is taken. View cart

Annual cost

$24000a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

FDA boxed warningPost treatment acute exacerbation of hepatitis b

Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of GENVOYA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue GENVOYA. If appropriate, anti-hepatitis B therapy may be warranted.

Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of GENVOYA. Hepatic function should be monitored closely in these patients. If appropriate, anti-hepatitis B therapy may be warranted.

Read this with the rest of the clinical information

About Genvoya

Overview

Genvoya is a prescription tablet containing elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide. It is a complete treatment for HIV-1 infection in adults and children weighing at least 25 kg who have not previously received antiretroviral treatment. It can also replace a stable HIV treatment regimen used for at least six months when HIV-1 levels are below 50 copies/mL, with no previous treatment failure or known resistance to its components. Three ingredients block enzymes HIV uses to multiply, while cobicistat blocks a group of enzymes called CYP3A.

What it treats

- HIV-1 infection in adults and children weighing at least 25 kg who have not previously received antiretroviral treatment. - HIV-1 infection as a replacement for a stable antiretroviral regimen used for at least 6 months, when HIV-1 RNA is below 50 copies/mL, with no history of treatment failure and no known resistance mutations affecting any component of Genvoya.

Safety information

Side effects

Nausea is the most common side effect of Genvoya, reported in at least 10% of patients. Serious side effects that warrant contacting a doctor include severe worsening of hepatitis B, new or worsening kidney problems, immune reconstitution syndrome (changes in the immune response that may need evaluation and treatment), lactic acidosis (a buildup of lactic acid in the blood), and severe liver enlargement with fat buildup. Kidney function needs to be checked before starting and during treatment. Interactions with other medicines can cause serious side effects, make Genvoya or other medicines less effective, and potentially lead to drug resistance.

FDA boxed warning

Post treatment acute exacerbation of hepatitis b

Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of GENVOYA. Hepatic function should be monitored closely in these patients. If appropriate, anti-hepatitis B therapy may be warranted.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

Before taking this medicine

Do not take Genvoya with alfuzosin; carbamazepine, phenobarbital or phenytoin; rifampin; lurasidone or pimozide; dihydroergotamine, ergotamine or methylergonovine; St. John’s wort; lomitapide, lovastatin or simvastatin; triazolam; or midazolam taken by mouth. It must not be taken with sildenafil when used as Revatio to treat pulmonary arterial hypertension. These combinations may cause serious or life-threatening reactions, reduce Genvoya’s effectiveness or lead to resistance. Other medicines may also interact with Genvoya, affecting its effectiveness or safety or those of the other medicines. All medicines and herbal products should be reviewed for interactions. Genvoya is not recommended during pregnancy and should not be started in pregnant individuals, because exposure to cobicistat and elvitegravir is substantially lower during pregnancy. Breastfeeding is not recommended because of the potential for HIV transmission. Genvoya is not recommended for patients weighing less than 25 kg. New or worsening kidney problems may occur. Kidney function and urine glucose and protein must be checked before starting and during treatment; people with chronic kidney disease also need blood phosphorus checks. Immune reconstitution syndrome, an inflammatory response as the immune system recovers, may require further assessment and treatment. Treatment must be stopped if symptoms or test results suggest lactic acidosis (a buildup of lactic acid) or pronounced liver toxicity, including severe liver enlargement with fat buildup.

Interactions

Genvoya should not be taken with other antiretroviral medicines used to treat HIV-1 infection. It can change the levels of medicines processed by enzymes called CYP3A or CYP2D6. Medicines that increase CYP3A activity can also change the levels of one or more ingredients in Genvoya. Tell your doctor about all prescription medicines, over-the-counter medicines and herbal products you use, including St. John’s wort. Genvoya has many potential drug interactions, so these should be checked before and during treatment.

Using Genvoya

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label GENVOYA (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE) TABLET [GILEAD SCIENCES, INC.] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.